Clinical trials: Stage II Chronic Lymphocytic Leukemia
Acute Myelogenous Leukemia, Graft Versus Host Disease
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor.
- Conditions
- Acute Myelogenous Leukemia, Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00144677
- Testing
- sirolimus, tacrolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease [uMRD < or 10^-4 in peripheral blood…
- Trial name
- BRAVE (NCT06524375)
- Testing
- Venetoclax, cBTKi Monotherapy
- Where
- 20 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
Chronic Lymphocytic Leukemia
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309881
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 18 sites in Germany
- Volunteers
- 75 people
- Sponsor
- German CLL Study Group
Lymphoma
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or…
- Trial name
- NCT00003245
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
INCB018424 in Patients With Advanced Hematologic Malignancies
The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT00674479
- Testing
- INCB018424
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Lymphocytic
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
This study will evaluate the effectiveness of an experimental drug called LMB-2 for treating chronic lymphocytic leukemia (CLL) in patients who have a protein called cluster of differentiation 25 (CD25) on their cancer cells.
- Conditions
- Leukemia, Lymphocytic, Chronic
- Trial name
- NCT00077922
- Testing
- LMB-2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00691015
- Testing
- rituximab, busulfan, carmustine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004084
- Testing
- indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Leukemia
Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in…
- Trial name
- NCT00262743
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Mayo Clinic
Leukemia, Acute Myeloid Leukemia
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
The goal of this clinical research study is to learn if giving busulfan and fludarabine before a stem cell transplant can help control the disease better than the standard method in patients with leukemia, lymphoma, multiple…
- Conditions
- Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT01572662
- Testing
- Fludarabine monophosphate, Busulfan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Azadirachta indica may be an effective treatment for chronic lymphocytic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of Azadirachta indica in treating patients with chronic…
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT01251250
- Testing
- laboratory biomarker analysis, western blotting, gene expression analysis
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01643603
- Testing
- Dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Methods of T Cell Depletion Trial (MoTD)
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- MoTD (NCT04888741)
- Testing
- Thymoglobulin, Cyclophosphamide, Cyclosporine
- Where
- 17 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Birmingham
Chronic Lymphocytic Leukemia
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune function in previously untreated…
- Trial name
- NCT03514017
- Testing
- Pembrolizumab, Ibrutinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Lymphoma
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00436618
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 277 people
- Sponsor
- Mayo Clinic
Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL).
- Conditions
- Diffuse Large B-cell Lymphoma, Indolent Non-hodgkin Lymphoma, Primary Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- VISMOLY (NCT01944943)
- Testing
- Vismodegib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- The Lymphoma Academic Research Organisation
Hematological Malignancies
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
The primary goal of the study is to determine the incidence and severity of acute Graft versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor Hematopoetic Stem Cell(HSC) transplant in patients…
- Trial name
- NCT01246206
- Testing
- Tacrolimus and Thymoglobulin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute